Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Goodwill (2022 - 2026)

Axsome Therapeutics' Goodwill history spans 5 years, with the latest figure at $12.0 million for Q1 2026.

  • On a quarterly basis, Goodwill changed 0.35% to $12.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $12.0 million, a 0.35% change, with the full-year FY2025 number at $12.0 million, changed 0.35% from a year prior.
  • Goodwill hit $12.0 million in Q1 2026 for Axsome Therapeutics, roughly flat from $12.0 million in the prior quarter.
  • Over the last five years, Goodwill for AXSM hit a ceiling of $12.0 million in Q2 2023 and a floor of $10.3 million in Q4 2022.
  • Historically, Goodwill has averaged $11.8 million across 5 years, with a median of $12.0 million in 2023.
  • Biggest five-year swings in Goodwill: rose 16.39% in 2023 and later decreased 0.35% in 2024.
  • Tracing AXSM's Goodwill over 5 years: stood at $10.3 million in 2022, then rose by 16.39% to $12.0 million in 2023, then changed by 0.0% to $12.0 million in 2024, then grew by 0.35% to $12.0 million in 2025, then changed by 0.0% to $12.0 million in 2026.
  • Business Quant data shows Goodwill for AXSM at $12.0 million in Q1 2026, $12.0 million in Q4 2025, and $12.0 million in Q3 2025.